In vivo study | In the maximum electroconvulsive seizure threshold (MEST) test in rats, SB-271046 in a wide range of doses, increasing the seizure threshold, the lowest effective oral dose is 0.1 mg/kg, and after 4 hours, the maximum effect is achieved. The level of anticonvulsant activity correlated well with SB-271046 blood concentrations (EC50 of 0.16 μm) and brain concentrations at 0.01 μm to 0.04 μm of C max. SB-271046-treated rats, a moderate cerebral penetrant (10%), with low blood clearance (7.7 mL/min/kg), good half-life (4.8 H), excellent oral bioavailability (>80%). SB-271046 treatment of the rat frontal cortex and dorsal hippocampus increased extracellular glutamate levels 3-fold and 2-fold, respectively, indicating that it can be used to treat cognitive and memory dysfunction. SB-271046 Wistar rats were fed orally at a dose of 20 mg/kg for 30 minutes and then trained. After 6 hours of training, it was found that Scopolamine(0.8 mg/kg, I. P.) treatment-induced amnesia. SB-271046 subcutaneous injection at a dose of 10 mg/kg) treatment of the frontal cortex of rats significantly increased the extracellular levels of glutamate and aspartate, which was Tetrodotoxin-dependent and reached a maximum, 375.4% and 215.3%, respectively, before injection. |